Clinical Trial Update: Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma [NA]

View source ↗

Summary

A clinical trial of Vorasidenib guided by AGX PET in recurrent and low-grade glioma is not yet recruiting, with Huashan Hospital listed as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Glioma
• Glioma
• Low-grade Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Huashan Hospital | Conditions: Glioma, Diffuse Glioma | NA | Status: NOT_YET_RECRUITING